References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-49. doi: 10.3322/caac.21669
- Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet 2018; 143(Suppl 2): S22-36. doi: 10.1002/ijgo.13865
- Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 95(Suppl 1): S43-103. doi: 10.1016/S0020-7292(06)60030-1
- Thomas GM, Dembo AJ, Myhr T, Black B, Pringle JF, Rawlings G. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery. Int J Gynecol Cancer 1993; 3: 193-8. doi: 10.1046/j.1525-1438.1993.03040193.x
- Gandy N, Arshad MA, Park WE, Rockall AG, Barwick TD. FDG-PET Imaging in cervical cancer. Semin Nucl Med 2019; 49: 461-70. doi: 10.1053/j.semnu-clmed.2019.06.007.
- Patel-Lippmann K, Robbins JB, Barroilhet L, Anderson B, Sadowski EA, Boyum J. MR imaging of cervical cancer. Magn Reson Imaging Clin N Am 2017; 25: 635-49. doi: 10.1016/j.mric.2017.03.007
- Palaniswamy SS, Borde CR, Subramanyam P. 18F-FDG PET/CT in the evaluation of cancer cervix: where do we stand today? Nucl Med Commun 2018; 39: 583-92. doi: 10.1097/MNM.0000000000000851
- Vinh-Hung V, Bourgain C, Vlastos G, Cserni G, De Ridder M, Storme G et al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer 2007; 7: 164. doi:10.1186/1471-2407-7-164
- Cancer.Net. Cervical Cancer: Statistics. [Internet]. American Society of Clinical Oncology (ASCO); c2005-21. [cited 2021 Aug 17]. Available from: https://www.cancer.net/cancer-types/cervical-cancer/statistics
- Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 2007; 110: 1738-44. doi: 10.1002/cncr.22974
- Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol 2010; 28: 2108-13. doi: 10.1200/JCO.2009.25.4151
- Yen TC, See LC, Lai CH, Tsai CS, Chao A, Hsueh S, et al. Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. Eur J Nucl Med Mol Imaging 2008; 35: 493-501. doi: 10.1007/s00259-007-0612-1
- Han S, Kim H, Kim YJ, Suh CH, Woo S. Prognostic value of volume-based metabolic parameters of 18F-FDG PET/CT in uterine cervical cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 2018; 211: 1112-21. doi: 10.2214/AJR.18.19734
- Miccò M, Vargas HA, Burger IA, Kollmeier MA, Goldman DA, Park KJ, et al. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. Eur J Radiol 2014; 83: 1169-76. doi: 10.1016/j.ejrad.2014.03.024
- Ho JC, Allen PK, Bhosale PR, Rauch GM, Fuller CD, Mohamed AS, et al. Diffusion-weighted magnetic resonance imaging as a predictor of outcome in cervical cancer after chemoradiation. Int J Radiat Oncol Biol Phys 2017; 97: 546-53. doi: 10.1016/j.ijrobp.2016.11.015
- Tavassoéli FA, Devilee P. IARC WHO classification of tumours, pathology and genetics tumours of the breast and female genital organs. Vol 4. 3rd edition. Lyon: IARC publications; 2003.
- Kurman RJ, Hedrick-Ellenson L, Ronnett BM. Blaustein’s pathology of the female genital tract. 6th edition. New York: Springer; 2011.
- Meads C, Davenport C, Małysiak S, Kowalska M, Zapalska A, Guest P, et al. Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation. BJOG 2014; 121: 398-407. doi: 10.1111/1471-0528.12460
- Chu Y, Zheng A, Wang F, Lin W, Yang X, Han L, et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. Nucl Med Commun 2014; 35: 144-50. doi: 10.1097/MNM.0000000000000026
- Pallardy A, Bodet-Milin C, Oudoux A, Campion L, Bourbouloux E, Sagan C, et al. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 2010; 37: 1270-8. doi: 10.1007/s00259-010-1417-1
- Bjurberg M, Brun E. Clinical impact of 2-deoxy-2-[18F] fluoro-D-glucose (FDG)-positron emission tomography (PET) on treatment choice in recurrent cancer of the cervix uteri. Int J Gynecol Cancer 2013; 23: 1642-6. doi: 10.1097/IGC.0b013e3182a50537
- Lai CH, Huang KG, See LC, Yen TC, Tsai CS, Chang TC, et al. Restaging of recurrent cervical carcinoma with dual-phase [18F] fluoro-2-deoxy-D-glucose positron emission tomography. Cancer 2004; 100: 544-52. doi: 10.1002/cncr.11928
- Yen TC, Lai CH, Ma SY, Huang KG, Huang HJ, Hong JH, et al. Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer. Eur J Nucl Med Mol Imaging 2006; 33: 1399-407. doi: 10.1007/s00259-006-0090-x
- Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004; 22: 2167-71. doi: 10.1200/JCO.2004.09.035
- Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007; 298: 2289-95. doi: 10.1001/jama.298.19.2289
- Kim YJ, Han S, Kim YS, Nam JH. Prognostic value of post-treatment 18F-fluorodeoxyglucose positron emission tomography in uterine cervical cancer patients treated with radiotherapy: a systematic review and meta-analysis. J Gynecol Oncol 2019; 30: e66. doi: 10.3802/jgo.2019.30.e66.
- Onal C, Guler OC, Reyhan M, Yapar AF. Long-term outcomes of cervical cancer patients with complete metabolic response after definitive chemoradiotherapy. J Gynecol Oncol 2021; 32: e74. doi: 10.1016/j.clon.2021.03.022
- Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, et al. Predictive role of post-treatment [18F] FDG PET/CT in patients with uterine cervical cancer. Eur J Radiol 2012; 81: e817-e822. doi: 10.1016/j.ejrad.2012.02.015